A statement of changes in beneficial ownership filed on September 18, 2026, disclosed that Thomas Fuchs, a director of GeneDx Holdings Corp., acquired 1,146 shares of Class A Common Stock through the settlement of restricted stock units on September 17, 2026.

Key Highlights

  • Reporting person: Thomas Fuchs, identified as a Director of GeneDx Holdings Corp. (NASDAQ:WGS)
  • Transaction date: September 17, 2026, with the filing submitted September 18, 2026
  • Shares acquired: 1,146 shares of Class A Common Stock via transaction code M (conversion of derivative security), at a price of $0
  • Post-transaction ownership: 1,146 shares of Class A Common Stock held directly following the reported transaction
  • RSU balance: 2,292 restricted stock units remain beneficially owned directly after the transaction
  • Vesting schedule: The RSU award vests in three equal installments on September 17, 2026, September 17, 2027, and September 17, 2028, subject to continued service

RSU Settlement Details for GeneDx Director Thomas Fuchs

According to the filing, Thomas Fuchs holds the position of Director at GeneDx Holdings Corp., a genomic testing and data company traded on NASDAQ under the symbol WGS. The transaction reported involves the settlement of restricted stock units, each of which, according to the filing, "represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration."

The filing reports that 1,146 RSUs were converted (transaction code M) into 1,146 shares of Class A Common Stock on September 17, 2026, at a recorded price of $0. This conversion reflects the first of three equal vesting installments. The filing states that the award shall vest in equal portions on September 17, 2026, September 17, 2027, and September 17, 2028, contingent on the reporting person's continued service to the issuer on each applicable vesting date. Following this transaction, Fuchs directly holds 2,292 RSUs still outstanding, consistent with the two remaining vesting installments. The filing was signed by Bridget Brown as attorney-in-fact on September 18, 2026.

What Was Disclosed

The filing discloses a director-level RSU settlement at GeneDx Holdings Corp., in which 1,146 restricted stock units converted to an equal number of Class A Common Stock shares at no cost, with 2,292 RSUs remaining under a three-year vesting schedule.